Trevi Therapeutics to Participate in Upcoming Conferences
Trevi Therapeutics to Participate in Upcoming Conferences
NEW HAVEN, Conn., May 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending investor, business development and medical conferences in May and June.
康涅狄格州纽黑文,2024 年 5 月 9 日/PRNewswire/-- Trevi Therapeutics, In 纳斯达克股票代码:TRVI)是一家处于临床阶段的生物制药公司,该公司正在开发用于治疗特发性肺纤维化(IPF)和难治性慢性咳嗽(RCC)的研究性疗法Haduvio(口服纳布啡ER),今天宣布,高级管理层将在5月和6月参加投资者、业务发展和医学会议。
The Citizens JMP Life Sciences Conference
May 13-14, 2024, New York, NY
Corporate Presentation: May 14 at 12:00 p.m. ET
Trevi Presenter: Jennifer Good, President and CEO
Citizens JMP 生命科学会议
2024 年 5 月 13-14 日,纽约州纽约
企业演示: 美国东部时间 5 月 14 日中午 12:00
特雷维主持人: 总裁兼首席执行官詹妮弗·古德
ATS 2024 International Conference
May 17-22, 2024, San Diego, CA
Session: A104: Advances in the Diagnosis and Treatment of ILD
Abstract: Nalbuphine Extended-release Reduces Cough Bouts in Patients With Idiopathic Pulmonary Fibrosis
Presentation: May 19, 3:00 p.m. - 4:15 p.m. PT
Location: San Diego Convention Center, Room 33A-C (Upper Level)
Presenter: Jacky Smith, MB, ChB, FRCP, PhD, Professor of Respiratory Medicine at the University of Manchester, and an Honorary Consultant at Manchester University NHS Foundation Trust. Director of the NIHR Manchester Clinical Research Facility, Respiratory Theme Lead in the NIHR Manchester Biomedical Research Centre and an NIHR Senior Investigator.
ATS 2024 国际会议
2024 年 5 月 17 日至 22 日,加利福尼亚州圣地亚哥
会话: A104:ILD 诊断和治疗的进展
摘要: 纳布啡缓释可减少特发性肺纤维化患者的咳嗽发作
演示: 太平洋时间 5 月 19 日下午 3:00-下午 4:15
地点: 圣地亚哥会议中心,33A-C 室(上层)
演示者: 杰基·史密斯,MB、ChB、FRCP、博士,曼彻斯特大学呼吸医学教授,曼彻斯特大学NHS基金会信托基金荣誉顾问。美国国立卫生研究院曼彻斯特临床研究机构主任、美国国立卫生研究院曼彻斯特生物医学研究中心呼吸学主题负责人和美国国立卫生研究院高级研究员。
Registration details: https://conference.thoracic.org/
Life Science Education Series: Chronic Cough – KOL Panel Discussion
Discussion: May 20, 12:30 p.m. - 2:30 p.m. PT
Location: San Diego, CA
Panel Members: Experts in the field of chronic cough include Professor Peter Dicpinigaitis, Professor Jacky Smith, and Professor Alyn Morice. Moderated by Oppenheimer's Senior Biotechnology Analyst Dr. Leland Gershell.
生命科学教育系列:慢性咳嗽 — KOL 小组讨论
讨论: 太平洋时间 5 月 20 日下午 12:30-下午 2:30
地点: 加利福尼亚州圣地亚哥
小组成员: 慢性咳嗽领域的专家包括彼得·迪皮尼盖蒂斯教授、杰基·史密斯教授和艾琳·莫里斯教授。由奥本海默的高级生物技术分析师利兰·格谢尔博士主持。
To register, email: k.mcmanus@trevitherapeutics.com
要注册,请发送电子邮件至: k.mcmanus@trevitherapeutics.com
2024 BIO International Convention
June 3-6, 2024, San Diego, CA
2024 BIO 国际大会
2024 年 6 月 3 日至 6 日,加利福尼亚州圣地亚哥
Oppenheimer's 2024 Montauk Life Sciences Summit
June 26-28, 2024, Montauk, NY
奥本海默的 2024 年蒙托克生命科学峰会
2024 年 6 月 26 日至 28 日,纽约州蒙托克
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Trevi is also developing Haduvio for prurigo nodularis. Haduvio is a dual ĸ-opioid receptor agonist and μ-opioid receptor antagonist that works both centrally in the brain as well as peripherally in the lungs and has the potential for a synergistic antitussive effect to treat chronic cough.
关于 Trevi Therapeutics, Inc
Trevi Therapeutics, Inc. 是一家处于临床阶段的生物制药公司,正在开发研究性疗法Haduvio(口服纳布啡ER),用于治疗特发性肺纤维化(IPF)和难治性慢性咳嗽(RCC)中的慢性咳嗽。特雷维还在为结节性瘙痒症开发Haduvio。Haduvio 是一种双重阿片类药物受体激动剂和 μ-阿片受体拮抗剂,可在大脑中枢和肺部外周起作用,有可能产生协同镇咳作用,治疗慢性咳嗽。
The impact of chronic cough is significant and often leads to a decline in patients' social, physical, and psychological quality of life. In IPF, chronic cough may lead to worsening disease and may be associated with a higher risk of progression, death, or need for lung transplant. There are no approved therapies for the treatment of chronic cough in IPF and current treatment options provide minimal relief to patients. RCC affects up to 10% of the adult population, and Haduvio's expansion into RCC has the potential to reach patients suffering from moderate to severe chronic cough. There are also no approved therapies for RCC in the US.
慢性咳嗽的影响是巨大的,通常会导致患者的社交、身体和心理生活质量下降。在IPF中,慢性咳嗽可能导致疾病恶化,并可能增加进展、死亡或需要进行肺移植的风险。IPF中没有经批准的治疗慢性咳嗽的疗法,目前的治疗方案对患者的缓解作用微乎其微。RCC影响多达10%的成年人群,而Haduvio向RCC的扩展有可能惠及患有中度至重度慢性咳嗽的患者。美国也没有批准的RCC疗法。
Parenteral nalbuphine is not scheduled by the U.S. Drug Enforcement Agency. Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.
美国缉毒局没有计划注射肠外纳布啡。特雷维打算提议将Haduvio作为口服纳布啡ER的商品名。其安全性和有效性尚未经过任何监管机构的评估。
For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.
欲了解更多信息,请访问 www.treviTherapeutic 然后关注 Trevi X (以前是 Twitter)和 领英。
Investor Contact
Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
投资者联系人
凯蒂·麦克马纳斯
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com
媒体联系人
罗莎莉亚·斯坎波利
914-815-1465
rscampoli@marketcompr.com
SOURCE Trevi Therapeutics, Inc.
来源 Trevi Therapeutics, Inc